Back to search results

Observational Study of Blood and Tissue Samples in Metastatic Cancer

This study is looking for ways to better diagnose and treat aggressive cancers that have spread. Researchers will collect blood, cheek swab, and tissue samples from patients with metastatic (cancer that has spread to other parts of the body) cancer who are having a biopsy or surgery. They will also review your medical records and may use archived (stored) samples. By studying changes in DNA and proteins in these samples, the researchers hope to find new diagnostic markers and potential drugs for aggressive tumor types. This study aims to understand how these cancers develop and progress, and to identify targets for personalized treatments.

Study design
This is an observational study with a planned enrollment of 50 participants. It is not a treatment study, but rather focuses on collecting and analyzing samples.
What's involved
You would provide blood and buccal (cheek) swab samples, and tissue samples during a standard biopsy or surgery. Your medical records would also be reviewed, and archived samples might be collected.
Compensation
Not stated in the trial record.
Follow-up
DNA alterations and proteomic changes will be measured through study completion, which can be up to five years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05530759

Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal

Recruiting
Not specifiedAges 18+Observational
Mayo Clinic
~50 participants
Updated 2026-06-09 on ClinicalTrials.gov
What's tested:Biopsy SpecimenBiospecimen CollectionArchived Biospecimen CollectionMedical Chart Review

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Deoxyribonucleic acid (DNA) alterations
Measured over Through study completion; up to five years
+1 more outcome measured

Conditions

Hematopoietic and Lymphoid System Neoplasm
Metastatic Malignant Solid Neoplasm

Explore related trials

Hematologic NeoplasmSolid Neoplasm

NCT05530759

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic in Rochester

    Rochester, Minnesotastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Aaron S. Mansfield, M.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients (or the legally authorized representative/guardian signing on behalf of the participant) must understand and provide written informed consent prior to initiation of any study-specific procedures
\>= 18 years of age
Patients must have a diagnosis of confirmed malignancy
Patient is a good medical candidate for a standard of care biopsy or surgical procedure to obtain tissue or has archival tissue available for analysis

Exclusion

Uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent
Inaccessible tumor for biopsy or patient does not have tumor tissue available for research use
Biopsy must not be considered to be more than minimal risk to the patient. Contraindications to percutaneous biopsy:
Significant coagulopathy that cannot be adequately corrected
Severely compromised cardiopulmonary function or hemodynamic instability
Lack of a safe pathway to the lesion
Inability of the patient to cooperate with, or to be positioned for, the procedure

What this trial measures

  • Deoxyribonucleic acid (DNA) alterationsThrough study completion; up to five years

    identify molecular targets for which therapeutic drugs may exist

  • Proteomic changes in both biopsies and resected tumorsThrough study completion; up to five years

    identify molecular targets for which therapeutic drugs may exist